Supreme Court to Hear Amgen Challenge to Securities Suit

The U.S. Supreme Court will consider Amgen's challenge to a securities lawsuit alleging the biotech company played down safety concerns about two drugs used to treat anemia.

Gupta Won't Testify

Former Goldman Sachs director Rajat Gupta won't take the stand in his own defense at his insider-trading trial, his lawyer said Sunday.

GE Weighs Cuts to Lending Unit

GE is considering breaking off chunks of its lending business, responding to investors' concerns about the risks of the financial sector.

Airbus Remains Upbeat

Aircraft manufacturer Airbus is maintaining an earlier target to sell around 600-650 planes in 2012 even as the marketplace has weakened in recent months, said the company's chief operating officer for customers.

Fed Colleague Backs Dimon

The New York Fed's chairman said in an interview that J.P. Morgan CEO James Dimon shouldn't step down from his post at the central bank.

LinkedIn Defends Reaction After Password Theft

LinkedIn moved to reassure customers about the security of their data, following a password theft that caused a black eye for the social-networking service.

Total Engages Myanmar Opposition

French oil giant Total is reaching out to opposition forces in Myanmar, where it operates an offshore natural-gas field, as the company seeks to adapt to new political reality in the Southeast Asian country.

Bond Market to Scrutinize Data

A set of economic indicators due out this week will take on heightened importance for bond investors feeling unsure about where the Federal Reserve stands on further economic stimulus.

China Data Signal Some Strength

China's exports and imports both rose sharply in May, while inflation slowed—hopeful signs for the world's No. 2 economy. Reduced price pressure also leaves room for more stimulus.

RAG-Stiftung Could Cancel Evonik IPO

The majority owner of Evonik Industries AG said Sunday it is continuing to sound out investors about the planned initial public offering of the chemicals company and it won't rule out cancelling the deal if it feels Evonik will be undervalued, the latest sign of how market turmoil is derailing share offerings.

Total Reaches Out to Myanmar Opposition

French oil giant Total is reaching out to opposition forces in Myanmar, where it operates an offshore natural-gas field, as the company seeks to adapt to new political reality in the Southeast Asian country.

A Diet for GE Capital

GE is considering breaking off big chunks of its lending business, heeding the wishes of investors who are uncomfortable that the conglomerate owns what amounts to one of the country's largest banks.

Big U.S. Banks Brace for Downgrades

Banks, bond issuers and investors are bracing for aftershocks from a wave of bank downgrades expected to hit the U.S. as soon as the coming week.

Clinical Studies Buoy J&J's Diabetes Drug

Data from advanced clinical studies of a new type of diabetes drug being developed by a unit of Johnson & Johnson showed it reduced a measure of blood sugar in patients with type 2 diabetes.

ANA, China Airlines Forge Growth Plans

China Airlines of Taiwan and All Nippon Airways of Japan disclosed plans to expand their international services, as the carriers contend with low-cost competitors and the effects of a weak economy.

Gupta Won't Testify

Former Goldman Sachs director Rajat Gupta won't take the stand in his own defense at his insider-trading trial, his lawyer said Sunday.

Apple to Announce Updates

Apple's conference for technology developers Monday morning in San Francisco will end months of speculation about some key hardware and software initiatives.

Kodak's Patent Allure Fades

Eastman Kodak's effort to whip up interest in the sale of its digital patent portfolio is flagging, complicating the 132-year-old photography pioneers odds of emerging from bankruptcy court.

Investor Unrest Emerges for Glencore-Xstrata Deal

The investor revolt sweeping the U.K. could claim an even bigger casualty: commodities giant Glencore's proposed $66 billion merger with miner Xstrata. At issue is a $267 million executive-retention package tied to the landmark deal.

Sanofi Diabetes Drug Shows Promise

Sanofi's Lantus insulin reduced blood-sugar levels to a greater degree than Merck's Januvia in people with Type 2 diabetes in a clinical trial.